Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT02334969 Completed - Ischemic Stroke Clinical Trials

Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

Start date: April 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Naoxintong Capsule in the secondary prevention of ischemic stroke by the multi-center, randomized,double-blind,placebo-controlled trial design project.

NCT ID: NCT02323685 Completed - Cerebral Ischemia Clinical Trials

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

Start date: December 2014
Phase: Phase 2
Study type: Interventional

Safety and effect of SANGUINATE on patients DCI following SAH.

NCT ID: NCT02320539 Completed - Clinical trials for Subarachnoid Hemorrhage

MicroRNA Diagnostics in Subarachnoid Hemorrhage 2

Start date: November 2014
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to validate results from a related trial (NCT01791257) and to compare the profile of microRNA in blood from patients suffering subarachnoid hemorrhage with and without systemic complications.

NCT ID: NCT02315443 Completed - Clinical trials for Acute Cerebral Ischemia

Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

FRONTIER
Start date: March 26, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

NCT ID: NCT02297984 Completed - Clinical trials for Acute Ischemic Stroke

Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke

Start date: October 2013
Phase:
Study type: Observational [Patient Registry]

Neuroglobin has shown rich neuroprotective effects against cerebral ischemia and hypoxia, and therefore has the potential to impact outcomes after acute ischemic stroke. Hypoxia inducible factor (HIF)-1α is neuroprotective in several models of experimental brain injury and is increased in brain after acute cerebral infarction in humans and experimental animals.The investigators sought to examine the changes in serum neuroglobin and HIF-1α concentrations in patients with acute ischemic stroke during the initial 96-h period after stroke and assessed the relation between them and the relation of them to prognosis of such patients with acute ischemic stroke.

NCT ID: NCT02284165 Completed - Ischemic Stroke Clinical Trials

Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke

Start date: May 2013
Phase: N/A
Study type: Observational

Retrospective analysis of Get With the Guidelines-Stroke data linked with Medicare claims and the AVAIL longitudinal data sets to assess patterns, predictors, and outcomes associated with the use of rehabilitation services following hospitalization for ischemic stroke. Primary completion defined as the end of primary analyses, consistent with the end of the PCORI Cycle I grant period. Study completion defined as acceptance of final research report and lay abstract by PCORI.

NCT ID: NCT02270294 Completed - Ischemic Stroke Clinical Trials

Acute Effects of Thai Traditional Massage on Cerebrovascular Reactivity in Ischemic Stroke Patients

Start date: October 1, 2014
Phase: N/A
Study type: Interventional

The investigators hypothesize that Acute Thai traditional massage will yield beneficial effects on cerebrovascular reactivity in ischemic stroke patients.

NCT ID: NCT02259738 Completed - Cerebral Infarction Clinical Trials

Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Human urinary kallidinogenase can promote the establishment of collateral circulation in the ischemic penumbra due to the stenosis or occlusion of middle cerebral artery and then increase the perfusion.

NCT ID: NCT02248233 Completed - Cerebral Infarction Clinical Trials

Nimodipine for Treating Acute Massive Cerebral Infarction

Start date: October 2014
Phase: Phase 4
Study type: Interventional

Massive cerebral infarction is an ischemic stroke caused by complete blockage of the internal carotid artery, middle cerebral artery, or their cortical branches. The widespread infarction, pathological severity and high fatality rate associated with massive cerebral infarction pose a major threat to affected patients. However, there is a lack of unified diagnostic criteria. Many researchers use Adams' classification, in which massive cerebral infarction is diagnosed when the following criteria are met: infarct size > 13 cm2; a major brain-feeding artery is involved; the focal site affects more than two cerebral lobes; infarct diameter line ≥ 3 cm in internal capsule of striatum. Prolonged cerebral ischemia/reperfusion can induce complex secondary changes in brain tissue, so the use of neuroprotective agents is very important. Remarkable progress has been made over the last decade in understanding the protective effect of calcium antagonists against cerebral ischemia. In particular, the liposoluble dihydropyridine Ca2+ antagonist nimodipine selectively acts on cerebral vessels and neurons and can protect ischemic brain tissue, providing a new way of treating ischemic cerebrovascular disease. Preclinical and clinical tests have shown that nimodipine has a protective effect on ischemic brain tissue, and indicate that patients should take the drug as soon as possible. However, there are no reports of double-blind, randomized, controlled clinical trials addressing the administration of nimodipine via intravenous drip within the time window for successful treatment of acute massive cerebral infarction.

NCT ID: NCT02239640 Completed - Ischemic Stroke Clinical Trials

Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry

Start date: August 21, 2014
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to assess clinical outcomes, and different factors that may affect these clinical outcomes such as systems of care, associated with the use of Covidien market-released neurothrombectomy devices intended to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion.